Wells Fargo upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $133.55 yesterday.

Hot Upgrades Upgrades

PBC Committee Opens The Door to $2.2B Opportunity For Intercept Pharma (ICPT) - WedbushApril 6, 2016 7:50 AM Intercept Pharmaceuticals (ICPT) Briefing Docs 'Mostly In-Line' - FBR CapitalApril 5, 2016 11:07 AM Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT) Following Positive Briefing DocsApril 5, 2016 10:32 AM Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - LeerinkApril 5, 2016 9:33 AM Intercept Pharma (ICPT) FDA Briefing Documents PostedApril 5, 2016 8:01 AM